World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

EFFECT OF SUBCUTANEOUS SEMAGLUTIDE VS. DAILY LIRAGLUTIDE ON BODY WEIGHT IN ADULTS WITH OVERWEIGHT OR OBESITY WITHOUT DIABETES: SYSTEMIC REVIEW AND META-ANALYSIS

Dr. Bashayer Dhaifallah Alanazi*

ABSTRACT

Objectives: To provide an overview understanding and evaluate the efficacy of semaglutide and liraglutide for weight management and loss in adults without diabetes. Methods: Randomized controlled trials studies comparing semaglutide to liraglutide as well as semaglutide to placebo were identified and collected using PubMed. Mean rate differences were extracted from eligible studies and used to synthesize the results. Results: 10 relevant studies with a total sample size of almost 8792 non-diabetic adult patients were included. Both, semaglutide and liraglutide, had a significant effect, however, semagutide had a higher effect on body weight loss than liraglutide. Also, semagutide had a positive effect on body weight loss in non-diabetic obese adults when compared to the control group that were medicated with a placebo medication. Conclusions: Semaglutide 2.4 mg has a higher efficacy in treating obesity in non-diabetic adults. Higher levels semaglutide has higher efficacy than lower levels. Also, semaglutide may be superior to liraglutide when it comes to managing body weight in non-diabetic adults diagnosed with obesity.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR